Cargando…

Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses

β-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which these properties are manifest in vivo is less clear. Conscious freely moving rats, instrumented for me...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Jillian G., Kemp, Philip, March, Julie, Fretwell, Laurice, Hill, Stephen J., Gardiner, Sheila M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of American Societies for Experimental Biology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371235/
https://www.ncbi.nlm.nih.gov/pubmed/21865315
http://dx.doi.org/10.1096/fj.11-192435
_version_ 1782235182156218368
author Baker, Jillian G.
Kemp, Philip
March, Julie
Fretwell, Laurice
Hill, Stephen J.
Gardiner, Sheila M.
author_facet Baker, Jillian G.
Kemp, Philip
March, Julie
Fretwell, Laurice
Hill, Stephen J.
Gardiner, Sheila M.
author_sort Baker, Jillian G.
collection PubMed
description β-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which these properties are manifest in vivo is less clear. Conscious freely moving rats, instrumented for measurement of heart rate (β1; HR) and hindquarters vascular conductance (β2; HVC) were used to measure receptor selectivity and ligand efficacy in vivo. CGP 20712A caused a dose-dependent decrease in basal HR (P<0.05, ANOVA) at 5 doses between 6.7 and 670 μg/kg (i.v.) and shifted the dose-response curve for isoprenaline to higher agonist concentrations without altering HVC responses. In contrast, at doses of 67 μg/kg (i.v.) and above, ICI 118551 substantially reduced the HVC response to isoprenaline without affecting HR responses. ZD 7114, xamoterol, and bucindolol significantly increased basal HR (ΔHR: +122±12, +129±11, and +59±11 beats/min, respectively; n=6), whereas other β-blockers caused significant reductions (all at 2 mg/kg i.v.). The agonist effects of xamoterol and ZD 7114 were equivalent to that of the highest dose of isoprenaline. Bucindolol, however, significantly antagonized the response to the highest doses isoprenaline. An excellent correlation was obtained between in vivo and in vitro measures of β1-adrenoceptor efficacy (R(2)=0.93; P<0.0001).—Baker, J. G., Kemp, P., March, J., Fretwell, L., Hill, S. J., Gardiner, S. M. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
format Online
Article
Text
id pubmed-3371235
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Federation of American Societies for Experimental Biology
record_format MEDLINE/PubMed
spelling pubmed-33712352012-06-27 Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses Baker, Jillian G. Kemp, Philip March, Julie Fretwell, Laurice Hill, Stephen J. Gardiner, Sheila M. FASEB J Research Communications β-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which these properties are manifest in vivo is less clear. Conscious freely moving rats, instrumented for measurement of heart rate (β1; HR) and hindquarters vascular conductance (β2; HVC) were used to measure receptor selectivity and ligand efficacy in vivo. CGP 20712A caused a dose-dependent decrease in basal HR (P<0.05, ANOVA) at 5 doses between 6.7 and 670 μg/kg (i.v.) and shifted the dose-response curve for isoprenaline to higher agonist concentrations without altering HVC responses. In contrast, at doses of 67 μg/kg (i.v.) and above, ICI 118551 substantially reduced the HVC response to isoprenaline without affecting HR responses. ZD 7114, xamoterol, and bucindolol significantly increased basal HR (ΔHR: +122±12, +129±11, and +59±11 beats/min, respectively; n=6), whereas other β-blockers caused significant reductions (all at 2 mg/kg i.v.). The agonist effects of xamoterol and ZD 7114 were equivalent to that of the highest dose of isoprenaline. Bucindolol, however, significantly antagonized the response to the highest doses isoprenaline. An excellent correlation was obtained between in vivo and in vitro measures of β1-adrenoceptor efficacy (R(2)=0.93; P<0.0001).—Baker, J. G., Kemp, P., March, J., Fretwell, L., Hill, S. J., Gardiner, S. M. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. Federation of American Societies for Experimental Biology 2011-12 /pmc/articles/PMC3371235/ /pubmed/21865315 http://dx.doi.org/10.1096/fj.11-192435 Text en © FASEB This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Communications
Baker, Jillian G.
Kemp, Philip
March, Julie
Fretwell, Laurice
Hill, Stephen J.
Gardiner, Sheila M.
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title_full Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title_fullStr Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title_full_unstemmed Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title_short Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
title_sort predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
topic Research Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371235/
https://www.ncbi.nlm.nih.gov/pubmed/21865315
http://dx.doi.org/10.1096/fj.11-192435
work_keys_str_mv AT bakerjilliang predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses
AT kempphilip predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses
AT marchjulie predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses
AT fretwelllaurice predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses
AT hillstephenj predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses
AT gardinersheilam predictinginvivocardiovascularpropertiesofbblockersfromcellularassaysaquantitativecomparisonofcellularandcardiovascularpharmacologicalresponses